No published articles yet for this condition. Check back soon.
0 published articles · Updated continuously
29 trials tracked for Short bowel syndrome: 23 in phase 3 or 4 and 7 with published results. The most-cited published study has 382 citations.
Showing the 29 most-cited and recently-updated of 29 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
In patients with short bowel syndrome, teduglutide consistently reduces parenteral support (PS) requirements. Across multiple phase 3 trials, treatment with teduglutide led to significant reductions in weekly PS volume, with many patients achieving at least a 20% reduction. For example, in one trial (NCT02682381), 13 of 59 patients achieved a ≥20% reduction in weight-normalized PN/IV volume at week 24, and in another (NCT03596164), the percent change from baseline in weekly PS volume was -49.55% and -52.52% in two groups. Longer-term data (NCT02949362) showed sustained reductions in PS volume over 156 weeks, with percent changes ranging from -10.72% to -43.09% at various intervals. Additionally, teduglutide reduced days per week of PS usage (e.g., -2.3 and -2.0 days in NCT03596164) and increased plasma citrulline (39.2% change in NCT02980666), suggesting improved intestinal absorption.
Glepaglutide, another GLP-2 analog, also demonstrated efficacy in reducing PS requirements. In a phase 3 trial (NCT03690206), glepaglutide significantly reduced weekly PS volume (change of -5.13 L/week vs. -2.85 for placebo, p=0.0039) and increased days off PS (18 vs. 7 days, p=0.0043). Five patients were weaned off PS entirely compared to none on placebo (p=0.016). However, a smaller trial (NCT04991311) showed a trend toward improved fluid absorption (841.6 vs. 1240.0 g, p=0.0585) that did not reach statistical significance. For Omegaven, a lipid emulsion, one trial (NCT00910104) demonstrated reversal of cholestasis (direct bilirubin ≤2.0 mg/dL) in 11.7% of patients vs. 6.4% on placebo (p=0.001).
Other interventions have been studied but with less robust evidence. A phase 4 trial of rtPA lock therapy (NCT02355743) and somatropin (NCT01380366) are included but no outcome data were reported. Teduglutide trials in pediatric or specific populations (e.g., NCT03268811, NCT03571516, NCT05027308) showed variable results, with some patients achieving ≥20% reduction in PS volume but others not, and no patients achieving complete weaning in some studies. Overall, the evidence supports teduglutide and glepaglutide as effective in reducing PS dependence, with Omegaven beneficial for cholestasis.
AI synthesis of 0 cited trials, updated Jul 31, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.